Evidence map›Paper›PMID 33089969›Full record

ArticleThe journal of pathology. Clinical research2021

An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification.

Haiyan Shi, Ying Shao, Weiguo Lu, Bingjian Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pathology. Clinical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Research Progress of HER2 in Cervical Carcinoma.Cancer management and research · 2026
    Review
  9. Review
  10. Molecular Features of HPV-Independent Cervical Cancers.Pathogens (Basel, Switzerland) · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Advances in cervical cancer: current insights and future directions.Cancer communications (London, England) · 2025
    Review
  16. Review
  17. Article
  18. Contemporary Review of Adenocarcinoma of the Cervix.Current treatment options in oncology · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Haiyan ShiDepartment of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China.
Ying ShaoDepartment of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China.
Weiguo LuCenter for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, Women's Hospital, Zhejiang University, Hangzhou, PR China.
Bingjian LuDepartment of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China.
Women's Hospital, School of Medicine, Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few studies have explored HER2 status in cervical adenocarcinoma, particularly in the gastric-type adenocarcinoma (GAC), a nonhuman-papillomavirus-related subtype with poor clinical outcomes. In this study, we investigated HER2 expression and amplification by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 209 well annotated cervical adenocarcinomas diagnosed using the International Endocervical Adenocarcinoma Criteria and Classification. IHC identified HER2 protein expression in 57.4% (123/209) of adenocarcinomas, of which 62 were IHC 1+ (negative), 38 2+ (equivocal) and 23 3+ (positive). HER2 amplification was found in 13 cases (6.2%) including 10 with IHC 3+ and 3 with IHC 2+. Among all the major histotypes of cervical adenocarcinoma, HER2 amplification was most common in GAC cases with a frequency of 14.7% (5/34). Moreover, HER2 amplification was more frequently associated with 2018 International Federation of Gynecology & Obstetrics (FIGO) stage III/IV, perineural involvement and ovarian spread (p < 0.05) while IHC 3+ was more common in patients with lymphovascular invasion and ovarian involvement (p < 0.05). Survival analysis indicated that FIGO stage III/IV, GAC, and p53 overexpression were associated with poor disease-specific survival and tumor recurrence (p < 0.05). In conclusion, HER2 amplification was present in a subset of adenocarcinomas, and more common in GAC, pointing to a potential benefit from trastuzumab treatment. HER2 overexpression does not identify gene amplification status in cervical adenocarcinoma; therefore, FISH is suggested for both IHC positive and equivocal cases. Further investigation on more cases with longer follow-up times is required to consolidate these findings.

Indexed as

Gene AmplificationAdenocarcinomaAdultAntineoplastic Agents, ImmunologicalBiomarkers, TumorClinical Decision-MakingErb-b2 Receptor Tyrosine KinasesFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedNeoplasm StagingPhenotypePredictive Value of TestsAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabcervical adenocarcinomagastric-typegene amplificationHER2HPVprognosis

Identifiers

PMID33089969
PMCPMC7737776
OpenAlexW3093634330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.